
501(c)3 transforming how LongCovid, ME/CFS, Lyme+ and Alzheimer’s are studied, diagnosed, and treated. Leading the #LongCovid Research Consortium.
United States
Joined October 2020
- Tweets3K
- Following2K
- Followers14.5K
- Likes3.6K
Pinned Tweet
From Crisis to Cure: PolyBio is supporting top HIV researchers to pivot into the study and treatment of Long COVID. Watch the full video to learn how this collaboration is being maximized & driving forward innovative research: youtu.be/6kC1lyY6hPc?si=adTg…
Day Two of PolyBio’s Convergence Summit is in full swing—today’s focuses are clinical trials, pathogens’ role in mitochondrial dysfunction, optimizing clinical care, and public-private partnerships in IACIs.
Zoom information: amacad-org.zoom.us/j/9297286…
Starting now! PolyBio’s Convergence Summit Day One kicks off with foundational research presentations on mechanisms of pathogen persistence across Long COVID, chronic Lyme disease, autoimmune diseases, and neurodegenerative diseases.
Zoom link: amacad-org.zoom.us/j/9297286…
TOMORROW—PolyBio’s inaugural Convergence Summit kicks off at 8:30 am EST with Scientific Director Dr. Amy Proal’s welcome address. She’ll highlight the main theme of the conference—pathogen persistence—and the new frontier it presents for chronic disease and aging.
Join information: polybio.org/virtual-summit/
This Wednesday, November 18th: PolyBio’s inaugural Convergence Summit kicks off at the American Academy of Arts & Sciences, with 3 days of live-streamed presentations highlighting the role of pathogens in chronic diseases.
You’ll hear about the latest advances in Long COVID, multiple sclerosis, neurodegenerative disease, autoimmune disorders, and the biological processes underlying aging.
Join information: polybio.org/virtual-summit/
Discussions will focus on the practical challenges that must be addressed to translate discoveries into validated diagnostics, clinical trials, and effective therapies for IACIs.
Full schedule: polybio.org/wp-content/uploa…
PolyBio’s inaugural Convergence Summit is coming up this Wednesday, November 18th to Friday, November 20th! Presentations will explore the latest advances in persistent infections and their emerging roles in conditions such as Long COVID, multiple sclerosis, neurodegenerative disease, autoimmune disorders, and the biological processes underlying aging.
Join information: polybio.org/virtual-summit/
Across the three days, presentations will run on one continuous pathway from the underlying biology of pathogen persistence; to detection, novel therapeutics, and scaling up healthcare innovations in infection-associated chronic diseases via public-private partnerships.
Full schedule: polybio.org/wp-content/uploa…
5
317
PolyBio’s inaugural Convergence Summit 2026 is fast approaching! From November 18 to 20, presentations will address evolving research on the relationship between pathogens and chronic diseases such as Long COVID, chronic Lyme disease, MS, Alzheimer’s, and more.
The meeting will bring together leading researchers, clinicians, biotech innovators and public health experts to address the rapid need for IACI diagnostics and treatments to translate from the lab bench to hospital bedside.
See the full summit schedule and access the link to join on November 18-20 here: polybio.org/polybio-converge…
6
288
Featured on @WCVB last night: PolyBio’s Scientific Director Dr. Amy Proal and PolyBio funder and collaborator Steve Pagliuca.
They highlighted the impact of Long COVID on patients’ quality of life—and how PolyBio’s research programs are rapidly validating tissue and biofluid-based diagnostic tests that will fill gaps in clinical care.
We’re pleased to announce the inaugural PolyBio Convergence Summit will take place this November 18 to 20.
Presentations will explore the latest advances in persistent infections and their emerging roles in conditions such as Long COVID, chronic Lyme disease, multiple sclerosis, Alzheimer’s, and aging. Discussions will focus on the practical challenges that must be addressed to translate these discoveries into validated diagnostics, clinical trials, and effective therapies.
Add the virtual schedule to your calendar here: calendar.google.com/calendar…
The final summit day on November 20th will focus on treatment of acute infections to prevent chronic illness, innovative technologies in persistence research, and genetic/viral retroelements in chronic disease.
Attendees can also join directly at the American Academy of Arts & Science’s Zoom link from November 18-20 to hear all talks throughout the conference: amacad-org.zoom.us/j/9297286…
Actively recruiting: Extended decentralized trial of a novel therapeutic device to reduce chronic pain in post-treatment Lyme disease
👉🏻Eligibility criteria below
The Sana Pain Reliever is a frequency-based therapeutic device that has been shown to reduce all-cause neuropathic pain. 1/
Additional markers including HRV and patient-reported changes to sleep quality will also be evaluated. Participants will be asked to complete several questionnaires and attend virtual visits throughout the trial period. 6/
1
1
199
Eligibility criteria:
• You have a clinical diagnosis of chronic Lyme disease or post-treatment Lyme disease
• You have a clinical diagnosis of neuropathic pain
• You are 18 years or older
• You live in the United States and are able to attend virtual visits
If interested, please reach out to [email protected] to apply.
*Note that this is a randomized study with a 1:1 ratio of participants assigned to the treatment versus sham control.
clinicaltrials.gov/study/NCT…






